All In Biotech

Drug Trial Radar · NCT00042068

A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis

A Multi-center, Double-Blind, Randomized, Parallel-Group Trial to Compare the Efficacy and Safety of Three Doses of Meloxicam (7.5, 15, and 22.5 mg) and Placebo in Patients With Rheumatoid Arthritis

Last checked: Nov 19, 2026Latest source record: Nov 1, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,000

Actual

Start

Jun 2002

Primary completion

Not stated

Study completion Jul 2003

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jul 24, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A 12-week trial consisting of 5 visits (6 if follow up is needed) to find out how effective and safe three different doses of meloxicam are compared with placebo in Rheumatoid Arthritis. Patient will take one dose of study medication daily.

Conditions

  • Arthritis, Rheumatoid

Interventions

  • MeloxicamDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response according to American College of Rheumatology 20% (ACR20) classificationTime frame: at 12 weeks

Locations

153 sites in 14 countries. Site status is shown where the registry gives one.

  • Suites 570 (research) & 600 (PI)

    Huntsville, Alabama

  • Suite 200

    Montgomery, Alabama

  • Suite 140

    Anchorage, Alaska

  • #106

    Glendale, Arizona

  • Suite 601

    Phoenix, Arizona

  • Suite 201

    Phoenix, Arizona

  • Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • Boehringer Ingelheim Investigational Site

    Pasadena, California

  • Suite 100

    Rancho Cucamonga, California

  • Boehringer Ingelheim Investigational Site

    Rancho Mirage, California

  • Suite 208

    San Diego, California

  • Suite 202

    San Diego, California

  • Suite 301

    San Leandro, California

  • Suite A

    Santa Maria, California

  • Westlake Medical Research

    Westlake Village, California

  • Suite 200

    Colorado Springs, Colorado

  • Suites 205 & 206

    Danbury, Connecticut

  • Suite 300

    Washington D.C., District of Columbia

  • Boehringer Ingelheim Investigational Site

    Delray Beach, Florida

  • Boehringer Ingelheim Investigational Site

    Gainsville, Florida

  • Boehringer Ingelheim Investigational Site

    Jacksonville, Florida

  • Boehringer Ingelheim Investigational Site

    Largo, Florida

  • Suite 202

    Miami, Florida

  • Boehringer Ingelheim Investigational Site

    Ocala, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Boehringer Ingelheim Investigational Site

    Orlando, Florida

  • Suite 2

    Orlando, Florida

  • Suite 406

    Safety Harbor, Florida

  • Boehringer Ingelheim Investigational Site

    Sarasota, Florida

  • Boehringer Ingelheim Investigational Site

    South Miami, Florida

  • Suite 101

    St. Petersburg, Florida

  • Radiant Research

    Stuart, Florida

  • Suite 203

    Tampa, Florida

  • Boehringer Ingelheim Investigational Site

    Zephyrhills, Florida

  • Boehringer Ingelheim Investigational Site

    Coeur d'Alene, Idaho

  • Suite 202

    Idaho Falls, Idaho

  • Boehringer Ingelheim Investigational Site

    Lake Forest, Illinois

  • Boehringer Ingelheim Investigational Site

    Rockford, Illinois

  • Boehringer Ingelheim Investigational Site

    Springfield, Illinois

  • Boehringer Ingelheim Investigational Site

    Indianapolis, Indiana

Showing 40 of 153 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.